2024
Radioresistant Pulmonary Oligometastatic and Oligoprogressive Lesions From Nonlung Primaries: Impact of Histology and Dose-Fractionation on Local Control After Radiation Therapy
Verma N, Laird J, Moore N, Hayman T, Housri N, Peters G, Knowlton C, Jairam V, Campbell A, Park H. Radioresistant Pulmonary Oligometastatic and Oligoprogressive Lesions From Nonlung Primaries: Impact of Histology and Dose-Fractionation on Local Control After Radiation Therapy. Advances In Radiation Oncology 2024, 9: 101500. PMID: 38699671, PMCID: PMC11063223, DOI: 10.1016/j.adro.2024.101500.Peer-Reviewed Original ResearchLocal recurrence-free survivalNon-lung primaryAssociated with higher local recurrence-free survivalProgression-free survivalBiologically effective doseLocal controlRadioresistant metastasesOverall survivalPulmonary metastasesPrimary cancerColorectal carcinomaAssociated with superior local controlMultivariate analysisPatients treated with radiotherapyRisk of local recurrenceMedian follow-up timeMultivariable Cox proportional hazards regressionInferior local controlMedian total doseSuperior local controlAssociated with decreased riskImpact of histologyMetastasis-free survivalRecurrence-free survivalLocal failureDose-volume Predictors of Radiation Pneumonitis Following Thoracic Hypofractionated Radiotherapy
Sasse A, Oh P, Saeed N, Yang D, Hayman T, Knowlton C, Peters G, Campbell A, Laird J, Housri N, Park H. Dose-volume Predictors of Radiation Pneumonitis Following Thoracic Hypofractionated Radiotherapy. International Journal Of Radiation Oncology • Biology • Physics 2024, 118: e5. DOI: 10.1016/j.ijrobp.2023.10.054.Peer-Reviewed Original ResearchHypofractionated radiation therapyRisk of gradeUltra-central tumoursRadiation pneumonitisLung V20Lung V5Central tumorsMultivariable logistic regression analysisSingle health care systemDose-volume predictorsDosimetric risk factorsGrade 5 toxicitySimilar local controlDose-fractionation regimensProbability of gradeProximal tracheobronchial treeLogistic regression analysisMATERIAL/METHODSHealth care systemPrimary endpointOverall survivalHypofractionated radiotherapyMultivariable analysisLung doseThoracic tumorsDosimetric Factors Associated with Esophagitis Following Hypofractionated Radiotherapy to the Thorax
Sasse, Oh P, Saeed N, Yang D, Peters G, Hayman T, Housri N, Laird J, Campbell A, Knowlton C, Park H. Dosimetric Factors Associated with Esophagitis Following Hypofractionated Radiotherapy to the Thorax. International Journal Of Radiation Oncology • Biology • Physics 2024, 118: e7-e8. DOI: 10.1016/j.ijrobp.2023.10.059.Peer-Reviewed Original ResearchHypofractionated radiation therapyTotal patientsOverall survivalLocal controlUltra-central lung tumorsMultivariable logistic regression analysisSignificant differencesComparable local controlGrade 3 esophagitisRisk of gradeCases of gradeProbability of gradeLogistic regression analysisMATERIAL/METHODSMean esophagus doseSingle healthcare systemEsophagus DmaxPrimary endpointHypofractionated radiotherapyDosimetric factorsMultivariable analysisEsophagus doseThoracic tumorsDosimetric variablesClinical trials
2018
CDKN2A Copy Number Loss Is an Independent Prognostic Factor in HPV-Negative Head and Neck Squamous Cell Carcinoma
Chen WS, Bindra RS, Mo A, Hayman T, Husain Z, Contessa JN, Gaffney SG, Townsend JP, Yu JB. CDKN2A Copy Number Loss Is an Independent Prognostic Factor in HPV-Negative Head and Neck Squamous Cell Carcinoma. Frontiers In Oncology 2018, 8: 95. PMID: 29670856, PMCID: PMC5893829, DOI: 10.3389/fonc.2018.00095.Peer-Reviewed Original ResearchDisease-free survivalNeck squamous cell carcinomaSquamous cell carcinomaOverall survivalHPV-negative HNSCCPrognostic factorsCell carcinomaPoor survivalLoss groupCDKN2A mRNAMedian disease-free survivalP16 expressionCopy number lossNumber lossMedian overall survivalReceipt of chemotherapyIndependent prognostic factorUseful prognostic factorHPV-negative headHigh p16 expressionProtein expression levelsHPV infectionCancer Genome AtlasBetter prognosisMultivariable analysis
2017
CDKN2A copy number loss in HPV- and HPV+ head and neck cancer to indicate poor prognosis: An integrated genomic and clinical TCGA analysis.
Chen W, Bindra R, Mo A, Hayman T, Husain Z, Contessa J, Gaffney S, Townsend J, Yu J. CDKN2A copy number loss in HPV- and HPV+ head and neck cancer to indicate poor prognosis: An integrated genomic and clinical TCGA analysis. Journal Of Clinical Oncology 2017, 35: 6060-6060. DOI: 10.1200/jco.2017.35.15_suppl.6060.Peer-Reviewed Original ResearchCopy number lossNumber lossP16 protein expression levelsDisease-free survivalTumor suppressor proteinMedian disease-free survivalMedian overall survivalOverall survivalGene transcriptionSuppressor proteinCDKN2A mRNAProtein expression levelsGenomic groupsCopy number ratioCancer Genome Atlas (TCGA) headGenomic measurementsHPV statusPoor prognosisNeck cancerExpression levelsLoss groupTCGA analysisProtein expressionP16 protein expressionCDKN2A
2015
Outcomes of resected pancreatic cancer in patients age ≥70
Hayman T, Strom T, Springett G, Balducci L, Hoffe S, Meredith K, Hodul P, Malafa M, Shridhar R. Outcomes of resected pancreatic cancer in patients age ≥70. Journal Of Gastrointestinal Oncology 2015, 6: 498-504. PMID: 26487943, PMCID: PMC4570916, DOI: 10.3978/j.issn.2078-6891.2015.038.Peer-Reviewed Original ResearchOutcomes of patientsAdjuvant chemoradiationOverall survivalCA19-9Patient agePancreatic cancerMultivariate analysisMedian patient ageUpfront surgical resectionPancreatic cancer patientsNeoadjuvant therapyPrimary endpointNodal statusSurgical resectionYounger patientsYear OSCancer patientsPancreatic carcinomaPatientsChemoradiationMortalitySignificant correlationOutcomesCancerMonths